NASDAQ:OXFD - Oxford Immunotec Global Stock Price, News, & Analysis

$13.42
-0.11 (-0.81 %)
(As of 06/26/2019 04:00 PM ET)
Today's Range
$13.26
Now: $13.42
$13.62
50-Day Range
$13.65
MA: $14.86
$16.31
52-Week Range
$11.66
Now: $13.42
$19.19
Volume252,300 shs
Average Volume145,165 shs
Market Capitalization$357.28 million
P/E Ratio26.31
Dividend YieldN/A
Beta0.42
Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for immunology and infectious diseases in the United States. It develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OXFD
CUSIPN/A
Phone44-0-12-3544-2780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.75 million
Cash Flow$0.6550 per share
Book Value$8.12 per share

Profitability

Net Income$120.78 million

Miscellaneous

Employees215
Market Cap$357.28 million
Next Earnings Date7/30/2019 (Estimated)
OptionableNot Optionable

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its earnings results on Thursday, May, 9th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.20) by $0.14. The business had revenue of $14.79 million for the quarter, compared to analyst estimates of $13.74 million. Oxford Immunotec Global had a net margin of 172.27% and a return on equity of 13.56%. The company's revenue for the quarter was up 26.6% compared to the same quarter last year. During the same quarter last year, the business earned ($0.40) earnings per share. View Oxford Immunotec Global's Earnings History.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Tuesday, July 30th 2019. View Earnings Estimates for Oxford Immunotec Global.

What guidance has Oxford Immunotec Global issued on next quarter's earnings?

Oxford Immunotec Global updated its FY 2019 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $69-72 million.

What is the consensus analysts' recommendation for Oxford Immunotec Global?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

Has Oxford Immunotec Global been receiving favorable news coverage?

Headlines about OXFD stock have trended negative this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Oxford Immunotec Global earned a media sentiment score of -2.5 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View News Stories for Oxford Immunotec Global.

Who are some of Oxford Immunotec Global's key competitors?

What other stocks do shareholders of Oxford Immunotec Global own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include Immunomedics (IMMU), Intel (INTC), AbbVie (ABBV), Gold Resource (GORO), Sangamo Therapeutics (SGMO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Halozyme Therapeutics (HALO).

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 45)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 58)
  • Mr. Matthew T.E. McLaughlin, Chief Financial Officer (Age 42)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 54)
  • Ms. Karen C. Koski, VP of Strategy & Investor Relations

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by many different of retail and institutional investors. Top institutional investors include Redmile Group LLC (7.52%), FIL Ltd (1.22%), Penn Capital Management Co. Inc. (1.00%), Penn Capital Management Co. Inc. (1.00%), Martingale Asset Management L P (0.62%) and EAM Global Investors LLC (0.29%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

Which major investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, Penn Capital Management Co. Inc., Penn Capital Management Co. Inc., New York State Common Retirement Fund and Campbell & CO Investment Adviser LLC. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Which major investors are buying Oxford Immunotec Global stock?

OXFD stock was purchased by a variety of institutional investors in the last quarter, including FIL Ltd, EAM Global Investors LLC, Marshall Wace LLP, Granite Investment Partners LLC, Martingale Asset Management L P, Acadian Asset Management LLC and BNP Paribas Arbitrage SA. View Insider Buying and Selling for Oxford Immunotec Global.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $13.42.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $357.28 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

What is Oxford Immunotec Global's official website?

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]


MarketBeat Community Rating for Oxford Immunotec Global (NASDAQ OXFD)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  217 (Vote Outperform)
Underperform Votes:  201 (Vote Underperform)
Total Votes:  418
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/26/2019 by MarketBeat.com Staff

Featured Article: What is the NASDAQ?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel